65,437 trials
Persistent Atrial Fibrillation · Longstanding Persistent Atrial Fibrillation
Primary: The Number of Participants Free From Atrial Fibrillation (AF), Atrial Flutter or Atrial Tachycardia While Off Class I and Class III Antiarrhythmic Drugs for at Least 4…
Renal Impairment
Primary: Maximum Plasma Concentration (Cmax) of Total Telotristat Ethyl, LP-778902 and LP-951757 — 3.81; 4.94; 533; 759 ng/mL
Inflammatory Bowel Disease (IBD)
Primary: Measure Antibody Concentrations in Immunosuppressed IBD Patients Who Receive High Dose and Standard of Care Dose Influenza Vaccine — 160; 160; 160; 160 Antibody Titer
Atrial Fibrillation · Stroke
Primary: Time in TTR, the Percentage of Time in the Therapeutic Range of INR Between 2.0-3.0. — 43.4; 49.1 percentage of time in therapeutic range
Attention Deficit Hyperactivity Disorder
Primary: Medication Continuity: The Number of Days Covered With Medicine — 108.8; 133.3 Days — p=0.04
Systemic Juvenile Idiopathic Arthritis
Primary: Percentage of Participants Who Achieved a Minimum Adapted American College of Rheumatology (ACR) Pediatric 30 Criteria — 100.0 Percentage of Participants
Depression
Primary: Medical Outcomes Survey Short Form (SF12) Mental Component Subscale (MCS) Score — 47.52; 48.94; 51.03; 51.11 score on a scale
Nasopharyngeal Nonkeratinizing Carcinoma · Recurrent Nasopharynx Carcinoma · Stage III Nasopharyngeal Carcinoma AJCC v7
Primary: Confirmed Response Rate (Complete Response or Partial Response) Based on RECIST Version 1.1 — 20.5 percentage of patients with a response
Idiopathic Pulmonary Fibrosis
Primary: Percentage of Participants With IPF Symptoms — 88.0; 51.8; 49.4; 42.9 Percentage of participants
Psoriasis
Primary: Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI90) at Week 24 — 10.0; 83.3 percentage of participants — p=< 0.001
Advanced Cancer
Primary: Recommended Phase 2 Dose: Maximum Tolerated Dose — 400 milligrams (mg)
Premedication · Endotracheal Intubation
Primary: Number of Patients With Prolonged Desaturation — 54; 53 Participants — p=0.38
Scabies · Yaws · Impetigo
Primary: Impetigo Prevalence at 12 Months — 79; 66; 20; 12 Cases of impetigo
Allergic Rhinitis · Allergic Rhinoconjunctivitis
Primary: Mean Total Symptom Score (TSS) After 10 Months of Treatment (Visit 6) Compared to Placebo — 10.01; 8.06; 8.19; 7.69 Score on a scale — p=0.057
Asthma
Primary: 'Well-controlled Asthma Week' - a Derived Binary Variable (Yes/No) — 34.4; 31.1; 44.4 Percentage — p=0.046